Ranitidine Tablets, USP 300 mg a). 15-count bottles (NDC 70934-287-15), b). 90-count bottles (NDC...

FDA Recall #D-0795-2020 — Class II — December 20, 2019

Recall #D-0795-2020 Date: December 20, 2019 Classification: Class II Status: Terminated

Product Description

Ranitidine Tablets, USP 300 mg a). 15-count bottles (NDC 70934-287-15), b). 90-count bottles (NDC 70934-287-90), Rx Only, Repackaged by: Northwind Pharmaceuticals North Brenheim, NY 12131

Reason for Recall

CGMP Deviations: Presence of NDMA impurity detected in product.

Recalling Firm

Denton Pharma, Inc. — North Blenheim, NY

Classification

Class II — May cause temporary or medically reversible adverse health consequences.

Product Type

Drugs

Product Quantity

467 bottles

Distribution

Nationwide

Code Information

a). N106851901, Exp. 11/30/2021 N106851902, Exp. 10/31/2021 b). C106851901, Exp. 11/30/2021 C106851902 Exp. 10/31/2021 C106851903 Exp. 02/28/2022 C106851904 Exp. 11/30/2021 C106851905 Exp. 05/31/2022

Status

Terminated

Voluntary / Mandated

Voluntary: Firm initiated